Upcoming Biosimilar IPOOne analyst already found that one of the new biosimilar drugs in the recent deal is along the same lines as this upcoming IPO that is estimated to be huge $. I think the rise in price today is the new presentation and as more analysts weigh in, I think we will see some favorable upgrades. I am surprised how cheap the March call options are, particular the $20's. The Dec $20 calls were close to $10 not long ago. The March $20 are less than $3.
~
https://www.fiercebiotech.com/story/samsung-and-biogen-plot-ipo-their-biosimilars-jv/2015-06-29